Dr Reddy’s Biologics Facility Receives Form 483 objections following US FDA inspection

Dr Reddy’s informed the Indian National Stock exchange on 12 October 2023 that the FDA issued a Form 483 with nine observations for Dr Reddy’s biologics manufacturing facility in Hyderabad.  The observations were issued after a product-specific pre-approval inspection of the facility by the FDA between 4 and 12 October 2023.